ORCID Profile
0000-0002-0794-3285
Current Organisations
INGM - Istituto Nazionale di Genetica Molecolare Romeo ed Enrica Invernizzi
,
Università degli Studi di Milano
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Related Links
Publications
LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion
Publisher: Springer Science and Business Media LLC
Date: 17-01-2022
DOI: 10.1038/S41588-021-00989-7
Abstract: How gene expression is controlled to preserve human T cell quiescence is poorly understood. Here we show that non-canonical splicing variants containing long interspersed nuclear element 1 (LINE1) enforce naive CD4
Ex vivo microRNA and gene expression profiling of human Tr1‐like cells suggests a role for miR‐92a and ‐125a in the regulation of EOMES and IL‐10R
Publisher: Wiley
Date: 28-09-2021
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Publisher: Wiley
Date: 12-2021
Abstract: The third edition of Flow Cytometry Guidelines provides the key aspects to consider when performing flow cytometry experiments and includes comprehensive sections describing phenotypes and functional assays of all major human and murine immune cell subsets. Notably, the Guidelines contain helpful tables highlighting phenotypes and key differences between human and murine cells. Another useful feature of this edition is the flow cytometry analysis of clinical s les with ex les of flow cytometry applications in the context of autoimmune diseases, cancers as well as acute and chronic infectious diseases. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid. All sections are written and peer‐reviewed by leading flow cytometry experts and immunologists, making this edition an essential and state‐of‐the‐art handbook for basic and clinical researchers.
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation
Publisher: Springer Science and Business Media LLC
Date: 23-07-2021
DOI: 10.1186/S13046-021-02023-4
Abstract: The yearly Think Tank Meeting of the Italian Network for Tumor Biotherapy (NIBIT) Foundation, brings together in Siena, Tuscany (Italy), experts in immuno-oncology to review the learnings from current immunotherapy treatments, and to propose new pre-clinical and clinical investigations in selected research areas. While immunotherapies in non-small cell lung cancer and melanoma led to practice changing therapies, the same therapies had only modest benefit for patients with other malignancies, such as mesothelioma and glioblastoma. One way to improve on current immunotherapies is to alter the sequence of each combination agent. Matching the immunotherapy to the host’s immune response may thus improve the activity of the current treatments. A second approach is to combine current immunotherapies with novel agents targeting complementary mechanisms. Identifying the appropriate novel agents may require different approaches than the traditional laboratory-based discovery work. For ex le, artificial intelligence-based research may help focusing the search for innovative and most promising combination partners. Novel immunotherapies are needed in cancer patients with resistance to or relapse after current immunotherapeutic drugs. Such new treatments may include targeted agents or monoclonal antibodies to overcome the immune-suppressive tumor microenvironment. The mode of combining the novel treatments, including vaccines, needs to be matched to the patient’s immune status for achieving the maximum benefit. In this scenario, specific attention should be also paid nowadays to the immune intersection between COVID-19 and cancer.
Related Organisations
INGM - Istituto Nazionale Di Genetica Molecolare Romeo Ed Enrica Invernizzi
Location: Italy
Università Degli Studi Di Padova Scuola Di Medicina E Chirurgia
Location: Italy
Related Funding Activities
No related grants have been discovered for Sergio Abrignani.